logo-loader
viewValiRx PLC

ValiRx advances as it wins patent protection pre-clinical drug to treat endometriosis

The gynaecological disorder occurs when tissue similar to the lining of the uterus, or endometrium, migrates outside of the womb, generally to the fallopian tubes, ovaries and tissue around the uterus

patent spelled out in coloured letters
The American authorities have provided the company with a boost

ValiRx Plc (LON:VAL) has won US patent protection for its pre-clinical drug VAL301, which is being developed for the treatment of endometriosis.

The gynaecological disorder occurs when tissue similar to the lining of the uterus, or endometrium, migrates outside of the womb, generally to the fallopian tubes, ovaries and tissue around the uterus.

READ: ValiRx surges as it continues “advanced conversations” with possible partners for lung cancer drug

The resulting symptoms are debilitating for an estimated 200mln women worldwide and the condition represents one of the biggest health issues for females of reproductive age, the company said. 

The market for drugs treating the condition is expected to grow to US$1.91bn by 2023.

"This US patent grant is excellent news for VAL301 and for our opportunity of trying to address this little known, but hugely widespread and debilitating chronic illness that affects a very substantial number of women around the world,” said chief executive, Dr Satu Vainikka.

“New targeted treatments with minimal side effects are needed, particularly when considering the target patient group - young women of child-bearing age.”

In early morning trading, ValiRX shares were up 10% at 2.75p.

 -- Adds share price --

Quick facts: ValiRx PLC

Price: 7.9 GBX

AIM:VAL
Market: AIM
Market Cap: £2.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ValiRx Plc enjoying strong industry interest in its cancer treatments

George Morris, chief operations officer at ValiRx Plc (LON:VAL), updates Proactive's Andrew Scott on developments across the company's portfolio. Morris says advanced conversations are continuing with possible partners as they look to press ahead with the development of their flagship...

on 19/7/18

2 min read